口腔癌治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、治療方法、分銷管道、地區和競爭格局分類，2021-2031年

全球口腔癌治療市場預計將從 2025 年的 23.8 億美元成長到 2031 年的 32.2 億美元，複合年成長率為 5.17%。

此領域涵蓋多種旨在治療口咽和口腔惡性腫瘤的治療性介入，包括手術切除、放射線治療以及免疫療法和化療等全身性療法。市場成長的主要驅動力是全球口腔鱗狀細胞癌發生率的上升，而口腔鱗狀細胞癌的發生率上升與酒精和菸草使用量的增加以及人類乳突病毒感染的增加密切相關。此外，強調早期診斷和篩檢的大規模公共衛生宣傳活動正在識別出更多合格治療條件的患者，並維持對多樣化治療方案的需求。

另一方面，新型生物製藥的高成本以及開發中國家醫療基礎設施的匱乏，對生物藥物的廣泛市場進入構成了重大障礙。這些物流和財務方面的挑戰往往阻礙了先進精準醫療技術在疾病負擔最重地區的推廣應用。國際癌症研究機構（IARC）引用的一項2024年研究表明，僅檳榔和無煙煙草的消費就導致全球超過12萬例口腔癌病例。這一數字凸顯了該疾病的巨大規模，以及對價格合理且擴充性的醫療解決方案的迫切需求。

市場促進因素

標靶治療和免疫療法的進步正在改變全球口腔癌治療市場，為過去治療選擇有限的轉移性或復發性口腔癌患者提供持續的治療效果。免疫查核點抑制劑，特別是PD-1拮抗劑的出現，與傳統細胞毒性療法相比，顯著提高了存活率，加速了高價值生物製藥的上市。例如，2024年6月發表於ASCO的一篇文章報道，一項針對頭頸癌患者的3期臨床試驗表明，在姑息化療中加入低劑量Nivolumab單抗，可將一年總生存率提高至35.5%，而單純化療的一年總生存率為20%。這些臨床成功凸顯了精準醫療的有效性，並顯著推動了醫藥投資，儘管新療法價格昂貴，但仍能提升市場價值。

同時，全球口腔鱗狀細胞癌發生率的上升是推動醫療介入需求成長的主要因素，因此亟需建立可擴展的治療系統。吸菸仍然是主要風險因素，但由於老齡化相關風險因素以及人類乳突病毒（HPV）相關惡性腫瘤的轉變，已開發地區的患者群體正在不斷擴大。根據英國口腔健康基金會發布的《2024年英國口腔癌現況報告》，英國每年新增口腔癌病例達10,825例，較過去十年增加了38%。這一成長趨勢凸顯了在主要市場提供多樣化治療方法的迫切性。例如，美國癌症協會預測，2024年美國將新增58,450例咽癌和口腔癌病例。

市場挑戰

新型生物製藥的高昂成本以及開發中國家醫療基礎設施的匱乏是限制全球口腔癌治療市場成長的主要障礙。包括標靶治療和免疫療法在內的先進療法價格昂貴，對於中低收入國家的支付者和患者而言往往難以負擔。醫療基礎設施的不足，例如缺乏診斷工具、專業的腫瘤中心以及訓練有素的醫護人員來管理複雜的治療方案，進一步加劇了這一經濟障礙。因此，在這些高負擔地區，有很大一部分合格的患者被迫依賴療效較差、過時的治療方法或接受安寧療護，從而限制了高附加價值治療產品的潛在市場規模。

各國在資金投入和醫療政策方面的差異進一步加劇了這種醫療服務取得的困難。世界衛生組織（世衛組織）2024年的全球調查發現，只有39%的參與國將基礎癌症管理納入了其公共資助的核心醫療服務體系。這項數據凸顯了阻礙口腔癌先進療法廣泛應用的嚴重後勤和資金不足。除非這些結構性和經濟性挑戰得到解決，否則創新藥物生產商將難以打入新興市場，即使全球疾病發生率不斷上升，其收入成長也將受到限制。

市場趨勢

人工智慧 (AI) 與治療計劃的融合正在從根本上改變全球口腔癌治療市場，顯著提升手術和放射治療的精準度。在強度調控放射治療(IMRT) 中，利用 AI 演算法自動勾畫腫瘤和危險器官輪廓的應用日益廣泛，不僅減少了人為誤差和計劃時間，還最佳化了惡性組織的劑量傳遞。該技術還有助於預測淋巴結轉移和淋巴管外侵犯，這對於確定是否需要輔助化療至關重要。 2025 年 7 月，《應用放射腫瘤學》雜誌報道，一種新的深度學習演算法預測這些情況的曲線下面積(AUC) 高達 0.91，顯著優於傳統的放射學評估，並簡化了複雜頭頸部惡性腫瘤的臨床工作流程。

同時，液態生物檢體和唾液生物標記的引入正成為非侵入性疾病監測和復發檢測的主要趨勢。與侵入性強且受腫瘤異質性限制的傳統組織切片檢查不同，液態生物檢體透過分析血液和唾液中的外泌體和循環腫瘤DNA（ctDNA），提供關於治療反應的即時資訊。這種方法能夠早期識別局部復發和殘留病灶，從而實現快速有效的挽救性治療，最終提高存活率。美國國立衛生研究院於2025年4月發表的一項研究表明，複合唾液生物標記組合在區分口腔鱗狀細胞癌和良性病變方面達到了88%的敏感性和80%的特異性，這表明腫瘤科醫生可以製定更精準的治療方案。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球口腔癌治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（鱗狀細胞癌、疣狀癌、小唾液腺癌、淋巴瘤、其他）
  • 依治療方法（標靶治療、化療、免疫療法）
  • 分銷通路（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美口腔癌治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲口腔癌治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區口腔癌治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲口腔癌治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲口腔癌治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球口腔癌治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Novartis AG
• Hospira, Inc.
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc.
• Lilly USA, LLC
• Merck & Co., Inc.
• Fresenius Kabi AG
• Accord BioPharma, Inc.
• Bristol-Myers Squibb Company
• Spectrum Pharmaceuticals, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Oral Cancer Treatment Market is projected to expand from USD 2.38 Billion in 2025 to USD 3.22 Billion by 2031, reflecting a compound annual growth rate of 5.17%. This sector encompasses a variety of therapeutic interventions, including surgical removal, radiation therapy, and systemic treatments such as immunotherapy and chemotherapy, designed to manage malignancies in the oropharynx and oral cavity. The market is primarily fueled by the rising global incidence of oral squamous cell carcinoma, which is strongly linked to high alcohol and tobacco usage, as well as the increasing prevalence of human papillomavirus infections. Additionally, broader public health campaigns emphasizing early diagnosis and screening are successfully identifying larger eligible patient groups, thereby maintaining demand for diverse therapeutic options.

Conversely, the high cost of new biological drugs and inadequate healthcare infrastructure in developing nations create significant obstacles to broad market access. These logistical and financial hurdles often prevent the adoption of advanced precision medicines in regions with the heaviest disease burden. A 2024 study cited by the International Agency for Research on Cancer noted that consumption of areca nut and smokeless tobacco alone accounted for over 120,000 oral cancer cases worldwide. This figure highlights the massive scale of the condition and the critical need for medical solutions that are both affordable and scalable.

Market Driver

Advancements in Targeted Therapies and Immunotherapy are transforming the Global Oral Cancer Treatment Market by providing lasting results for patients with metastatic or recurrent disease who previously had few alternatives. The arrival of immune checkpoint inhibitors, particularly PD-1 antagonists, has notably improved survival rates compared to traditional cytotoxic treatments, driving the uptake of high-value biological drugs. For example, ASCO Publications reported in June 2024 that a phase 3 trial adding low-dose nivolumab to palliative chemotherapy for head and neck cancer raised the one-year overall survival rate to 35.5%, compared to 20% with chemotherapy alone. Such clinical successes confirm the efficacy of precision medicine and stimulate significant pharmaceutical investment, boosting the market's value despite the high prices of new therapies.

Concurrently, the rising global prevalence of Oral Squamous Cell Carcinoma serves as a major volume driver for medical interventions, requiring scalable treatment frameworks. While tobacco use remains a leading risk factor, the patient demographic in developed regions is expanding due to age-related susceptibility and a shift toward HPV-associated malignancies. In the UK, the Oral Health Foundation's 'The State of Mouth Cancer UK Report 2024' indicated that annual diagnoses reached 10,825, a 38% increase over the last decade. This growing prevalence emphasizes the urgent need for diverse treatment modalities in key markets. Illustrating the regional impact, the American Cancer Society projected that 58,450 new cases of pharynx and oral cavity cancer would be diagnosed in the United States in 2024.

Market Challenge

The exorbitant cost of new biological medications and limited healthcare infrastructure in developing countries constitute a major barrier to the growth of the Global Oral Cancer Treatment Market. Advanced therapies, including targeted agents and immunotherapies, carry high price tags that are frequently unaffordable for payers and patients in low- and middle-income nations. This financial exclusivity is exacerbated by insufficient medical infrastructure, which lacks the necessary diagnostic tools, specialized oncology centers, and trained staff needed to manage complex treatment regimens. Consequently, a large portion of the eligible patient population in these high-burden regions relies on less effective, older modalities or receives palliative care, restricting the total addressable market for premium therapeutic products.

This lack of access is further underscored by gaps in national funding and health policies. A 2024 global survey by the World Health Organization revealed that only 39% of participating countries included basic cancer management in their funded core health services. This statistic points to severe logistical and financial deficits that hinder the widespread adoption of advanced oral cancer treatments. As long as these structural and economic inadequacies remain, manufacturers of innovative drugs will struggle to penetrate emerging markets, limiting revenue growth despite the increasing global incidence of the disease.

Market Trends

The Integration of Artificial Intelligence in Treatment Planning is fundamentally altering the Global Oral Cancer Treatment Market by improving the accuracy of surgical and radiation procedures. AI algorithms are increasingly utilized to automate the contouring of tumors and at-risk organs during Intensity-Modulated Radiation Therapy (IMRT), reducing human error and planning time while optimizing dose delivery to malignant tissues. This technology also helps predict nodal metastasis and extranodal extension, which are crucial for determining the need for adjuvant chemotherapy. In July 2025, Applied Radiation Oncology reported that a new deep-learning algorithm predicted these conditions with an Area Under the Curve (AUC) of 0.91, significantly outperforming traditional radiological assessments and streamlining clinical workflows for complex head and neck malignancies.

Simultaneously, the Implementation of Liquid Biopsy and Salivary Biomarkers is becoming a key trend for non-invasive disease monitoring and recurrence detection. Unlike standard tissue biopsies, which are invasive and limited by tumor heterogeneity, liquid biopsies analyze exosomes and circulating tumor DNA (ctDNA) in blood or saliva to provide real-time insights into treatment response. This method allows for the early identification of local recurrence and residual disease, facilitating timely salvage interventions that can improve survival rates. A study published by the National Institutes of Health in April 2025 showed that a combined salivary biomarker panel achieved 88% sensitivity and 80% specificity in distinguishing oral squamous cell carcinoma from benign lesions, enabling oncologists to tailor management plans with greater precision.

Key Market Players

• Novartis AG
• Hospira, Inc.
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc.
• Lilly USA, LLC
• Merck & Co., Inc.
• Fresenius Kabi AG
• Accord BioPharma, Inc.
• Bristol-Myers Squibb Company
• Spectrum Pharmaceuticals, Inc

Report Scope

In this report, the Global Oral Cancer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Cancer Treatment Market, By Type

• Squamous Cell Carcinoma
• Verrucous Carcinoma
• Minor Salivary Gland Carcinomas
• Lymphomas
• others

Oral Cancer Treatment Market, By Treatment

• Targeted Therapy
• Chemotherapy
• Immunotherapy

Oral Cancer Treatment Market, By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

Oral Cancer Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oral Cancer Treatment Market.

Available Customizations:

Global Oral Cancer Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Cancer Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Squamous Cell Carcinoma, Verrucous Carcinoma, Minor Salivary Gland Carcinomas, Lymphomas, others)
  • 5.2.2. By Treatment (Targeted Therapy, Chemotherapy, Immunotherapy)
  • 5.2.3. By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Oral Cancer Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oral Cancer Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Oral Cancer Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Oral Cancer Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Distribution Channel

7. Europe Oral Cancer Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oral Cancer Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Oral Cancer Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Oral Cancer Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Oral Cancer Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Oral Cancer Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Oral Cancer Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Oral Cancer Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Oral Cancer Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Oral Cancer Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Oral Cancer Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Oral Cancer Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Oral Cancer Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Oral Cancer Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Oral Cancer Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Oral Cancer Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Distribution Channel

10. South America Oral Cancer Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Oral Cancer Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Oral Cancer Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Oral Cancer Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Oral Cancer Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Hospira, Inc.
• 15.3. Teva Pharmaceutical Industries Ltd
• 15.4. Pfizer Inc.
• 15.5. Lilly USA, LLC
• 15.6. Merck & Co., Inc.
• 15.7. Fresenius Kabi AG
• 15.8. Accord BioPharma, Inc.
• 15.9. Bristol-Myers Squibb Company
• 15.10. Spectrum Pharmaceuticals, Inc

16. Strategic Recommendations

17. About Us & Disclaimer